CClinicalTrials.gg
Status unknownNCT05312086MDmuscleXLHUpdated Apr 5, 2022

Muscle Abnormalities in Children With XLH

An interventional study of MRI in Muscle Weakness and XLH, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown. Open to participants aged 5 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
5 Years to 17 Years
Sex
All
01

Study summary

XLH rickets is a rare disease with muscle weakness. Fat parameters such as IMAT and intraMAT could be increased in this disease. IMAT and intraMAT will be calculated on MRI for 11 XLH children versus 20 typically developing children. The investigator will compare the percentage of IMAT in the XLH group versus control group and the difference concerning the intraMAT between the two groups.

Read the detailed description

Single-center, prospective, non-randomized, controlled study with XLH and healthy volunteer children.

This study involves performing muscle MRI in healthy child volunteers to assess and compare the structure and composition of muscles to those of muscles in children with XLH pathology (muscle MRI of XLH patients is performed as part of standard medical care).

During this study we will have two groups: XLH group and a control group with typically developing children. In the XLH group, composed of 10 patients aged between 5 ans 17 years, female or male and ongoing growth (lesser bone age than 15 years old), have XLH and the most severe radiological deformities,clinical complications (pain and muscular weakness), have already done a muscle MRI of the lower limb during their follow-up.

The control group composed of 20 healthy volunteers aged between 5 ans 17 years old, female or male and without any endocrine pathology. A muscle MRI is necessary for healthy volunteers.

Every child will be alone After signing the informed consent by the 2 parents, the patient or the healthy volunteer and his parents, the MRI assessment will be performed on the same day.

Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, i.e. approximately 45 minutes.

Performing MRI does not require the injection of contrast products or radiopharmaceuticals.

02

Conditions studied

  • Muscle Weakness
  • XLH

Keywords

  • XLH rickets
  • IMAT
  • intraMAT
  • muscle weakness
  • MRI
03

In context

Muscle Weakness

601 studies on the registry are indexed under Muscle Weakness; 99 are open to participants now.

This study's planned enrollment of 30 is below the median of 46 across 444 interventional studies indexed under Muscle Weakness.

Browse Muscle Weakness studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria common criteria to the 2 groups:

  • Age: between 5 and 17 years.
  • Sex: male or female.
  • Informed consent, signed by both parents or holder of parental autority after being informated of the study.
  • Affiliation to a social security schema or having the right to.

Inclusion criteria for XLH Patients :

  • Patient suffer of X-linked hypophosphatemia rickets.
  • Severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities).
  • Growth in progress (bone age less than 15 years).
  • Child under conventional treatment: patient responding to conventional treatment or
  • under treatment with Burosumab (patient in treatment failure under treatment conventional).

incluion criteria for helthy volunteers :

  • Healthy voluntary subjects, not suffering from XLH.
  • Matching by age (+/- 6 months) and sex.

Exclusion Criteria common to the 2 groups :

  • Not being able to stay still during the MRI examination (approximately 45 min).
  • Growth completed.
  • History of lower limb surgery.
  • Contraindications to MRI
  • Holders of parental authority under AME.
  • Holders of parental authority under tutorship / curatorship.

Exclusion criteria for Healthy volunteers :

  • Patients with endocrine, contracted or muscular pathology.
  • Patient receives a long-term treatment.
  • Patients with a high athletic level.
  • BMI-IOTF \<20 or> 27.8
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    patients with X-linked hypophosphatemic

    Patient group composed of 10 patients aged between 5 to 17 years old, female or male, with X-linked hypophosphatemic (XLH) rickets, severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities) and ongoing growth (lesser bone age than 15 years old), child under conventional treatment

    Other: MRI

  • Other
    healthy volunteers

    control group composed of 20 helthy volunteers aged between 5 to 17 years old, female or male, without any endocrine pathology, not suffering from XLH, matching by age (+/- 6 months) and sex

    Other: MRI

Interventions

  • OtherMRI

    Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes. Performing MRI does not require the injection of contrast products or radiopharmaceuticals.

06

What researchers measure

Primary outcomes

  1. Quantify and compare muscle composition in XLH children versus healthy control children to demonstrate a link between muscle function and muscle quality.

    calculation of inter-muscular adipose tissue will be done in cm2

    Time frame: 1 day

Secondary outcomes

  1. Measurement of muscle strength on force platforms, during gait analysis. Power test by mechanography of the jump (bipod and monopodal). Grasping test and correlation of fatty infiltration and functional data.

    The Outcome Measure is BMI (Kg/m²)

    Time frame: 1 day

  2. Quantitative analysis of the muscles of the lower limbs (volume and length)

    The Outcome Measure is BMI (Kg/m²)

    Time frame: 1 day

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05312086
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Apr 5, 2022
Start date
Apr 15, 2022 (estimated)
Primary completion
Jun 15, 2023 (estimated)
Completion
Jun 15, 2023 (estimated)
Last update
Apr 5, 2022

Study contacts

Agnés LINGLART, Pr
Contact
agnes.linglart@aphp.fr
0145217116
Philippe WICART, Pr
Contact
p.wicart@aphp.fr
0144494310

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion